MANNKIND CORP

Explore why MannKind’s biotech ambition faces steep financial hurdles, its stock volatility, and what it must change to regain investor trust.

Explore MannKind Corp’s breakthrough with two new FDA approvals, turning high‑risk biotech into a potential revenue engine for investors.

Explore MannKind’s 2026 biotech journey: a $1.23B company navigating volatile stock, negative P/E, and a therapeutic pipeline targeting diabetes, cancer, and autoimmune diseases.

FDA approves MannKind’s Furoscix ReadyFlow autoinjector for heart‑failure and kidney‑disease fluid overload, boosting MNKD shares after a $50 M raise.

Explore MannKind Corp’s biopharma journey: diabetes & cancer therapies, volatile Nasdaq stock, $1.26B cap, and future growth prospects.

Discover MannKind Corp’s $1.4B biotech journey: from diabetes breakthroughs to market highs and lows, navigating R&D risks while pushing innovative therapies.

Explore why MannKind’s stock fell from a $6.51 peak to $4.52, the challenges its biotech pipeline faces, and what investors need to watch for future growth.

FDA approves Afrezza inhaled insulin for kids – MannKind’s breakthrough offers teens a quick, injection‑free diabetes option, boosting control and adherence.

Discover how MannKind Corporation’s 15% revenue surge and partnership with United Therapeutics fuel its growth, expanding inhalation therapies for pulmonary hypertension and beyond.

Explore MannKind Corp’s biotech journey: high‑growth P/E, volatile Nasdaq price, and innovative therapies for diabetes, cancer, and autoimmune conditions.